Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNCH NASDAQ:KPRX NASDAQ:LIAN NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$7.30$7.89$2.00▼$16.10$11.72M1.185,025 shsN/AKPRXKiora Pharmaceuticals$2.50-4.9%$2.44$1.76▼$3.39$11.08M-0.444,525 shs15,859 shsLIANLianBio$0.16+15.0%$0.13$0.27▼$4.99$17.28M0.231.04 million shs1,698 shsSHPHShuttle Pharmaceuticals$0.45-7.8%$0.74$0.38▼$6.19$2.66M0.181.37 million shs2.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-2.01%-10.43%-44.91%-46.12%KPRXKiora Pharmaceuticals-4.94%-6.72%-0.40%+26.26%-21.63%LIANLianBio-15.71%+26.13%-0.71%+52.75%-63.32%SHPHShuttle Pharmaceuticals-7.82%-13.52%-41.79%-50.49%-90.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$7.30$7.89$2.00▼$16.10$11.72M1.185,025 shsN/AKPRXKiora Pharmaceuticals$2.50-4.9%$2.44$1.76▼$3.39$11.08M-0.444,525 shs15,859 shsLIANLianBio$0.16+15.0%$0.13$0.27▼$4.99$17.28M0.231.04 million shs1,698 shsSHPHShuttle Pharmaceuticals$0.45-7.8%$0.74$0.38▼$6.19$2.66M0.181.37 million shs2.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-2.01%-10.43%-44.91%-46.12%KPRXKiora Pharmaceuticals-4.94%-6.72%-0.40%+26.26%-21.63%LIANLianBio-15.71%+26.13%-0.71%+52.75%-63.32%SHPHShuttle Pharmaceuticals-7.82%-13.52%-41.79%-50.49%-90.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNCHFinch Therapeutics Group 0.00N/AN/AN/AKPRXKiora Pharmaceuticals 2.00Hold$10.00300.00% UpsideLIANLianBio 0.00N/AN/AN/ASHPHShuttle Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SHPH, LIAN, KPRX, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/18/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/4/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/27/2026KPRXKiora Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/A$4.38 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$1.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/AKPRXKiora Pharmaceuticals-$10.84M-$2.71N/AN/AN/AN/A-59.30%-41.23%8/7/2026 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ASHPHShuttle Pharmaceuticals-$11.72M-$4.77N/AN/AN/AN/A-408.34%-138.15%N/ALatest SHPH, LIAN, KPRX, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SHPHShuttle PharmaceuticalsN/A-$0.43N/A-$0.43N/AN/A5/8/2026Q1 2026KPRXKiora Pharmaceuticals-$0.58-$0.58N/A-$0.58$1.50 millionN/A3/31/2026Q4 2025SHPHShuttle PharmaceuticalsN/A$0.06N/A$0.06N/AN/A3/25/2026Q4 2025KPRXKiora Pharmaceuticals-$0.70-$1.60-$0.90-$1.60$1.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNCHFinch Therapeutics GroupN/A3.873.87KPRXKiora PharmaceuticalsN/A6.686.68LIANLianBioN/A10.0610.06SHPHShuttle PharmaceuticalsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNCHFinch Therapeutics Group21.77%KPRXKiora Pharmaceuticals76.97%LIANLianBio74.85%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipFNCHFinch Therapeutics Group44.90%KPRXKiora Pharmaceuticals0.05%LIANLianBio7.59%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataKPRXKiora Pharmaceuticals104.43 million4.43 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableSHPHShuttle Pharmaceuticals55.85 million5.11 millionNot OptionableSHPH, LIAN, KPRX, and FNCH HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals (NASDAQ:SHPH) Shares Up 0.6% - Still a Buy?May 27, 2026 | americanbankingnews.comShuttle Pharmaceuticals Holdings Inc SHPHMay 19, 2026 | morningstar.comMShuttle Pharmaceuticals Holdings, Inc.May 15, 2026 | edition.cnn.comShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining RigsMay 14, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Completes Merger and PIPE FinancingMay 7, 2026 | tipranks.comE.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin MinerMay 7, 2026 | globenewswire.comShuttle to Acquire United Dogecoin in Push to Build Public DOGE Mining PlatformMay 2, 2026 | finance.yahoo.comWhy is SHPH stock soaring today? Dogecoin mining pivot sparks rallyMay 2, 2026 | msn.comShuttle Pharmaceuticals Transforms into Dogecoin Mining PowerhouseMay 1, 2026 | tipranks.comUnited Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining OperationMay 1, 2026 | newsfilecorp.comNShuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin MinerApril 30, 2026 | newsfilecorp.comNRETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 27, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 26, 2026 | newsfilecorp.comNE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public OfferingMarch 12, 2026 | markets.businessinsider.comE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public OfferingMarch 12, 2026 | globenewswire.comShuttle Pharmaceuticals Announces $3.5 Million Public OfferingMarch 6, 2026 | newsfilecorp.comNShuttle Pharma Extends Consulting Agreement With Interim Co-CEOFebruary 2, 2026 | tipranks.comUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | cantechletter.comCUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Accelerates Equity Payment in Asset DealDecember 29, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026TMC Forges a New EV Supply Chain at the Bottom of the SeaBy Jeffrey Neal Johnson | May 12, 2026GitLab’s Price Recovery Gains Traction—Time to Get On Board?By Thomas Hughes | June 4, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026SHPH, LIAN, KPRX, and FNCH Company DescriptionsFinch Therapeutics Group NASDAQ:FNCH$7.30 0.00 (0.00%) As of 06/5/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Kiora Pharmaceuticals NASDAQ:KPRX$2.50 -0.13 (-4.94%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.52 +0.02 (+0.60%) As of 06/5/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.LianBio NASDAQ:LIAN$0.16 +0.02 (+15.04%) As of 06/5/2026LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Shuttle Pharmaceuticals NASDAQ:SHPH$0.45 -0.04 (-7.82%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.43 -0.03 (-5.95%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
